Tenderwize
Wróć do wyszukiwania

Non-exclusive rebate agreement for Infliximab (ATC L04AB02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2027 · 246 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab (ATC-Code nach WHO: L04AB02)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No minimum purchase volumes and actual demand unknown; may lead to low or no revenue.

The buyer may terminate the Open-House if an exclusive rebate agreement is concluded, typically 8-12 months after publi...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Establish non-exclusive rebate agreements for Infliximab (ATC L04AB02) for intravenous infusion
  • Supply of pharmaceutical products to AOK PLUS insured persons in Saxony and Thuringia
Pokaż pełne podsumowanie

This is an Open-House model for non-exclusive rebate agreements under §130a(8) SGB V for the drug Infliximab (ATC L04AB02) for intravenous infusion. The buyer is AOK PLUS (Saxony and Thuringia). The procedure is open to all pharmaceutical companies meeting participation requirements. No minimum purchase volumes are guaranteed; actual demand is unknown. The contract runs until 30 April 2027. The notice clarifies that this is not a public procurement under EU Directive 2014/24/EU but is published for transparency. No estimated value is provided. Submission is electronic via DTVP, with confidentiality obligations. The first submission deadline is 5 May 2025; later deadlines are provided in separate documents.

Ryzyka

No minimum purchase volumes and actual demand unknown; may lead to low or no revenue.

The buyer may terminate the Open-House if an exclusive rebate agreement is concluded, typically 8-12 months after publi...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company within the meaning of §4(18) AMG

Eligibility

  • Must submit a declaration on exclusion grounds (§§123,124 GWB)

Administrative

  • Must submit a declaration on EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576)

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive rebate agreement for Infliximab (ATC L04AB02)

Open-House model for non-exclusive rebate agreements for the active substance Infliximab (intravenous infusion). All interested pharmaceutical companies can participate if they meet the conditions. No negotiation or exclusivity. Volume unknown.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

May 2025 - Apr 2027

Kategoria

Pharmaceutical products

Termin

Expired May 05, 2025

Szczegóły zamówienia

Data publikacji
24 Mar 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
189631-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3